Showing results (101-110 of 142) with videos related to

Sort By:
Pageof 15
Cancer Treatment Reports|May 1, 1986
Phase II study of low-dose methotrexate in advanced osteosarcoma followed by escalation after disease progression: a study of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research on Treatment of CancerD J Wagener, A T van Oosterom, J H Mulder, et al.
Anticancer Research|November 1, 1988
Preclinical pharmacokinetics of the antitumor antibiotic deshydroxy-sparsomycin in beagle dogsZ Zylicz, D J Wagener, M Garzotto, et al.
Investigational New Drugs|February 1, 1990
Pharmacokinetics of the antitumor antibiotic n-pentyl-sparsomycin in beagle dogsZ Zylicz, D J Wagener, M Garzotto, et al.
European Journal of Cancer & Clinical Oncology|March 1, 1983
Altered intracellular enzyme activity of monocytes and lymphocytes in Hodgkin's diseaseP H de Mulder, P D Mier, B E de Pauw, et al.
Anticancer Research|November 1, 1989
Modulation of the in vitro cytotoxicity of seven anticancer drugs by protein synthesis inhibition using sparsomycinZ Zylicz, H P Hofs, D J Wagener, et al.
Pediatric Pulmonology|October 27, 1999
Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosisM Rosenfeld, J Emerson, F Accurso, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Antitumour activity and retinotoxicity of ethyldeshydroxy-sparsomycin in miceH P Hofs, D J Wagener, D De Vos, et al.
Investigational New Drugs|December 1, 1988
In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor modelsZ Zylicz, D J Wagener, H van Rennes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1993
Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-P] in advanced gastric cancerE J Roelofs, D J Wagener, T Conroy, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Phase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupD J Wagener, R Somers, A Santoro, et al.
Pageof 15